SNYSanofi

$43.16

SNY as reported

Sanofi reported €43.6B of revenue over the trailing twelve months, +6.2% on the year before. 10 reported series are charted on this page, each one as filed.

€43.6B

Revenue, trailing twelve months · to FY2025 · +6.2% against the twelve months before

Net Income
€7.81B

Net Income · +41% year on year · trailing twelve months to FY2025

Free Cash Flow
€8.93B

Free Cash Flow · +21% year on year · trailing twelve months to FY2025

Op Margin
15%

Op Margin · trailing twelve months to FY2025

Every series Ryufin has for SNY, trailing twelve months
SeriesLatestYear on yearAs of
Revenue€43.6B+6.2%FY2025
Net Income€7.81B+41%FY2025
EPS€6.37+44%FY2025
Gross Margin77%n/aFY2025
Op Margin15%n/aFY2025
Net Margin18%n/aFY2025
ROE11%n/aFY2025
ROA6.2%n/aFY2025
ROIC6.1%n/aFY2025
Free Cash Flow€8.93B+21%FY2025

Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.

Revenue & ProfitSanofi (SNY)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com